347 related articles for article (PubMed ID: 19380767)
21. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
22. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
23. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
24. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
[TBL] [Abstract][Full Text] [Related]
25. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
[TBL] [Abstract][Full Text] [Related]
26. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
27. TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection.
Nazmi A; Mukherjee S; Kundu K; Dutta K; Mahadevan A; Shankar SK; Basu A
Neurobiol Dis; 2014 Sep; 69():235-47. PubMed ID: 24909816
[TBL] [Abstract][Full Text] [Related]
28. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-12 induces an effective antitumor response in malignant mesothelioma.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Scott B; Robinson BW
Am J Respir Cell Mol Biol; 1998 Nov; 19(5):738-46. PubMed ID: 9806738
[TBL] [Abstract][Full Text] [Related]
30. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
31. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
[TBL] [Abstract][Full Text] [Related]
32. Toll-like receptor 7 agonist imiquimod prevents the progression of SLE in MRL/lpr mice via inhibiting the differentiation of T follicular helper cells.
Duan X; Shen C; Zhang X; Wu L; Chen J; Ma B; Wang Q; Sun P; Lan Y; Su C
Int Immunopharmacol; 2020 Mar; 80():106239. PubMed ID: 32007709
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
34. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
35. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors.
Currie AJ; van der Most RG; Broomfield SA; Prosser AC; Tovey MG; Robinson BW
J Immunol; 2008 Feb; 180(3):1535-44. PubMed ID: 18209049
[TBL] [Abstract][Full Text] [Related]
36. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
37. Effect of TLR3 and TLR7 activation in uterine NK cells from non-obese diabetic (NOD) mice.
Lin Y; Ren L; Wang W; Di J; Zeng S; Saito S
J Reprod Immunol; 2009 Oct; 82(1):12-23. PubMed ID: 19560213
[TBL] [Abstract][Full Text] [Related]
38. Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.
Hackstein H; Hagel N; Knoche A; Kranz S; Lohmeyer J; von Wulffen W; Kershaw O; Gruber AD; Bein G; Baal N
PLoS One; 2012; 7(8):e43320. PubMed ID: 22927956
[TBL] [Abstract][Full Text] [Related]
39. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
40. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
